Pfizer Abrysvo by Pfizer Inc. - RSV vaccine targets seniors and pregnant women

Pfizer Abrysvo is the kind of product you notice when a nurse wheels a cooled metal tray into a dim hospital corridor, vials clinking softly as expectant mother and grandfather read the label twice. The respiratory syncytial virus (RSV) vaccine from Pfizer aims at two very different age groups, but one shared fear: severe lung infections.

Dual-target RSV protection strategy

Abrysvo is a bivalent RSV vaccine that targets both RSV-A and RSV-B subgroups, designed for adults aged 60 and older and for pregnant women to protect their newborns in the first months of life. According to Pfizer’s vaccine lead Annaliesa Anderson, the scientific team focused on stabilizing the prefusion F protein to trigger strong neutralizing antibodies.

In adults 60 and over, Abrysvo is given as a single intramuscular dose, usually into the upper arm muscle, and it has shown meaningful efficacy against RSV-associated lower respiratory tract disease in phase 3 trials. For pregnant women, the same formulation is administered during the second or third trimester, with maternal antibodies crossing the placenta to reduce RSV-related hospitalizations in infants from birth through six months.

Regulatory approvals and indications

Regulators in the United States approved Abrysvo for adults 60 years and older in May 2023 after reviewing phase 3 data from the RENOIR trial, where the vaccine reduced RSV-associated lower respiratory tract disease with a favorable safety profile. Later in 2023, the U.S. Food and Drug Administration also cleared Abrysvo for use during pregnancy to protect infants from RSV-related lower respiratory tract infection and severe disease.

Abrysvo has secured marketing authorization from the European Commission as well, covering both the older adult and maternal immunization indications, which makes it one of the first RSV vaccines available for pregnant women in the EU. The label in Europe specifies administration between weeks 24 and 36 of gestation and recommends a single dose regimen before the RSV season, aligning with national immunization guidelines.

How Abrysvo works in the body

Abrysvo is based on stabilized prefusion F glycoprotein antigens from RSV-A and RSV-B, presented in a nonadjuvanted formulation that aims to mimic the viral surface and induce neutralizing antibodies. In older adults, this response helps prevent RSV from infecting cells in the lower respiratory tract, reducing the risk of pneumonia, bronchiolitis and hospital visits.

For pregnant women, Abrysvo’s mechanism hinges on maternal-fetal antibody transfer: after vaccination, the mother’s immune system produces RSV-specific antibodies that move through the placenta to the fetus, so the newborn carries a ready-made antibody shield during the first critical months of life. Pfizer scientists describe this as borrowing the mother’s immune memory to cover the infant until their own system matures.

Clinical trial results in seniors

In the RENOIR study, a randomized, double-blind phase 3 trial including around 34,000 adults aged 60 and older, Abrysvo demonstrated vaccine efficacy of roughly 66 to 89 percent against RSV-associated lower respiratory tract disease depending on case definition and severity. Pfizer reported that the trial met its primary endpoint and showed consistent protection across age subgroups, including those over 70.

The safety profile in older adults was acceptable, with most adverse events being mild to moderate injection site pain, fatigue and headache, and serious adverse events occurring at similar rates to placebo. Javier Díez-Domingo, one of the clinical investigators, noted that any additional layer of RSV protection was valuable for frail seniors who already face risks from influenza and COVID-19.

Maternal immunization data

For the maternal indication, the MATISSE phase 3 trial evaluated Abrysvo in pregnant women, focusing on RSV-related hospitalizations and severe lower respiratory tract disease in their infants from birth through six months. The study showed a reduction in medically attended severe RSV infections in babies whose mothers received Abrysvo compared to those whose mothers had placebo.

Safety monitoring in MATISSE tracked both maternal and neonatal outcomes, and the overall data supported the benefit-risk balance, although regulators and Pfizer continue post-marketing surveillance to watch for rare events. In national guidelines, maternal RSV vaccination with Abrysvo is often coordinated with other pregnancy vaccines like influenza and Tdap, but administered in separate injections.

Packaging, storage and practical handling

Abrysvo comes as a sterile suspension in single-dose vials that must be stored refrigerated at 2 to 8 degrees Celsius, protected from light. In a busy clinic, that translates into a pharmacist sliding cold cardboard boxes from a humming vaccine fridge, checking expiry dates and gently swirling each vial before use, avoiding vigorous shaking.

Healthcare professionals administer Abrysvo as an intramuscular injection, typically in the deltoid muscle, and the vaccine should not be frozen because freezing can damage the protein structure and reduce efficacy. In Germany and other European markets, practices follow handling instructions aligned with the summary of product characteristics, which detail storage times outside the refrigerator and disposal of unused doses.

Competing RSV vaccines and positioning

Abrysvo entered a competitive RSV landscape that includes GSK’s Arexvy for older adults and monoclonal antibody products such as nirsevimab for infants. Compared with Arexvy, Abrysvo differentiates itself through its maternal indication, offering a vaccine-based path to infant protection rather than relying only on monoclonal antibody prophylaxis.

In investor presentations, Pfizer executives emphasize Abrysvo as part of a broader vaccines franchise that spans pneumococcal and meningococcal products, aiming to smooth revenue volatility as COVID-19 vaccine demand declines. CEO Albert Bourla has described RSV prevention as a multi-decade opportunity, reflecting demographic trends of aging populations and heightened focus on respiratory disease.

Pricing, reimbursement and availability

Exact Abrysvo pricing varies by market and contract, but in the United States the list price for the adult dose is set in a range comparable to other adult vaccines, and coverage often runs through Medicare Part D and commercial insurance plans. In Europe, reimbursement decisions are made at the country level, and many states are still working through cost-effectiveness assessments for both the older adult and maternal programs.

Abrysvo is available through hospital vaccination clinics, primary care practices and obstetric services, typically ordered via standard vaccine wholesalers. In Germany, the RSV vaccine segment is developing, and national experts continue to debate which risk groups should be prioritized as Abrysvo and alternative options roll out through the autumn and winter seasons.

Safety monitoring and contraindications

Abrysvo is contraindicated for individuals with a known severe allergic reaction to any component of the vaccine, and Pfizer documents warn clinicians to be ready for managing rare anaphylactic events using standard emergency protocols. Post-marketing safety systems, such as VAERS in the United States, collect reports of adverse events following Abrysvo vaccination and help regulators identify any unexpected patterns.

The company advises that Abrysvo can be administered alongside other vaccines at different injection sites, but healthcare providers should consider the overall reactogenicity profile when scheduling multiple shots on the same day. For pregnant women, shared decision-making with obstetricians is common practice, weighing the burden of RSV in local hospitals against individual health factors.

Market impact and Pfizer stock context

Abrysvo adds a new revenue stream in Pfizer’s vaccines portfolio, complementing pneumococcal products like Prevnar and counterbalancing the downshift from pandemic-era COVID-19 vaccine sales. Analysts follow uptake rates in seniors and maternal programs as an indicator of whether RSV immunization will become a routine, seasonal vaccination similar to influenza.

On Xetra, Pfizer Inc. stock trades via its listing linked to the US7170811035 ISIN, with RSV vaccine performance, including Abrysvo, contributing to sentiment around the company’s longer-term post-COVID transition.